Phaseline

Targets › MAPT

MAPT (Microtubule-associated protein tau): drug programs, companies and trials

18 programs from 17 companies in 21 trials: 11 Phase 1, 6 Phase 2, 4 Phase 3; Neurology, Other, Immunology; next expected readout Dec 2026.

Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. (UniProt, P10636)

Open in Phaseline: the race on MAPT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, IrvineMK-6240
tau PET tracer, binds to tau tangles in the brain
MAPTPhase 3Alzheimer DiseaseDec 2026
RocheTrontinemab
Anti-tau antibody targeting phosphorylated tau
MAPTPhase 3Alzheimers Disease; Alzheimer's DiseaseFeb 2028
Bristol-Myers SquibbBMS-986446
Anti-microtubule-binding region (MTBR) tau monoclonal antibody
MAPTPhase 2Alzheimer Disease, Early Onset; Alzheimer's DiseaseDec 2026
Columbia University18F-MK6240
Tau PET imaging tracer that binds to tau protein aggregates
MAPTPhase 2Alzheimer DiseaseMay 2027
University Hospital, ToulouseFlortaucipir
Tau-specific PET tracer
MAPTPhase 2Alzheimer DiseaseJan 2029
Scott Mcnallyflutemetamol F 18
Amyloid-beta PET imaging agent
MAPTPhase 2Cognitive ImpairmentSep 2030
Adam BoxerAADvac1
Active immunotherapy targeting tau pathology
MAPTPhase 2Progressive Supranuclear Palsy(PSP)Sep 2030
Adam BoxerLM11A-31
Small molecule targeting tau protein and neuroinflammation
MAPTPhase 2Progressive Supranuclear Palsy(PSP)Sep 2030
Amyloid SolutionAS-S603
Small molecule targeting amyloid-beta and tau aggregates
APP, MAPTPhase 1HealthyDec 2026
Texas Tech University Health Sciences CenterCurcumin
Polyphenolic compound targeting amyloid-beta aggregation and tau pathology; crosses blood-
ABCB1, APP, MAPTPhase 1BioavailabilityDec 2026
Eli Radiopharma[18F]Flortaucipir Injection
Tau neurofibrillary tangle (NFT) PET imaging agent - binds to aggregated tau protein
MAPTPhase 1AD - Alzheimer's DiseaseDec 2026
NuravaxDUVAX
Vaccine targeting amyloid-beta and tau proteins
APP, MAPTPhase 1Alzheimer DiseaseApr 2027
Voyager TherapeuticsVY7523
Monoclonal antibody targeting pathological tau
MAPTPhase 1Alzheimer's Disease (AD)May 2027
Tharick Pascoal18F-MK-6240
tau neurofibrillary tangle PET imaging agent
MAPTPhase 1Alzheimer DiseaseMay 2027
Arrowhead PharmaceuticalsARO-MAPT-SC
Antisense oligonucleotide targeting MAPT mRNA for reduction of tau protein
MAPTPhase 1Alzheimer DiseaseJun 2027
UCB Biopharma SRLBepranemab (UCB0107)
Microtubule-associated protein tau inhibitor
MAPTPhase 1Progressive Supranuclear PalsyDec 2027
Institute for Molecular MedicineAV-1980R
Recombinant protein tau vaccine targeting pathological tau
MAPTPhase 1Alzheimer DiseaseJun 2029
OligomerixOLX-07010
tau self-association inhibitor
MAPTPhase 1Alzheimer Disease–

Conditions

Alzheimer Disease (8) Alzheimer's Disease (2) Alzheimers Disease (2) Progressive Supranuclear Palsy(PSP) (2) AD - Alzheimer's Disease (1) Bioavailability (1) Alzheimer Disease, Early Onset (1) Alzheimer's Disease (AD) (1) Healthy (1) Progressive Supranuclear Palsy (1) Cognitive Impairment (1)

Modalities

small molecule (11), antibody (3), protein or peptide (2), mixed (2)

Companies

Adam Boxer (2) Eli Radiopharma (1) Texas Tech University Health Sciences Center (1) Bristol-Myers Squibb (1) Roche (1) Columbia University (1) Institute for Molecular Medicine (1) Voyager Therapeutics (1) Amyloid Solution (1) University Hospital, Toulouse (1) Arrowhead Pharmaceuticals (1) Tharick Pascoal (1) University of California, Irvine (1) Nuravax (1) Oligomerix (1) UCB Biopharma SRL (1) Scott Mcnally (1)

Related targets

APP (3) ABCB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.